

8 November 2017

ASX ANNOUNCEMENT

L-Dex® Abstracts to be Presented at San Antonio Breast Cancer Symposium

Brisbane, Australia and Carlsbad, Calif.- ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status, is pleased to announce that four abstracts, containing data from independent clinical studies, have been accepted and will be presented at the San Antonio Breast Cancer Symposium, 5th – 9th December 2017.

These new studies further support the value of prospective surveillance using L-Dex for the early detection of subclinical lymphoedema and subsequent reduction in chronic breast cancer related lymphoedema (BCRL) rates.

The four accepted abstracts are:

- L-Dex® surveillance of breast cancer-related lymphoedema: A retrospective study
Primary author - Koelmeyer LA
- Low rates of chronic breast cancer related lymphedema (BCRL) in a cohort of high-risk patients undergoing prospective surveillance with bioimpedance spectroscopy (BIS)
Primary author - Kaufman D, MD
- Utilization of BIS in the prevention of chronic breast cancer related lymphedema
Primary author - Kaufman D, MD
- The impact of a structured surveillance protocol using bioimpedance spectroscopy (BIS) on preventing breast cancer related lymphedema (BCRL) in high-risk patients
Primary author - Whitworth P, MD

“These studies add to the growing body of clinical evidence on how physicians are able to manage their cancer patients and limit their progression of BCRL using L-Dex. We are very pleased to continue to see that L-Dex, used in a clinical setting, has such positive impact on reducing the impact on patients of this debilitating disease,” said Richard Carreon, Managing Director and CEO of ImpediMed.

The University of Texas Health San Antonio Cancer Center, the American Association for Cancer Research, and Baylor College of Medicine will be hosting the 2017 San Antonio Breast Cancer Symposium, 5th – 9th Dec, at the Henry B. Gonzalez Convention Center. The symposium provides news on state-of-the-art breast cancer research, including experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease.

The abstracts will be published and available online 5th December.

Richard Carreon
Managing Director & CEO

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO

Morten Vigeland, ImpediMed CFO

T: +1 (760) 585-2100

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@we-buchan.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., and a European office in Thessaloniki, Greece, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed was the first company to receive FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men, for its L-Dex[®] device. In addition, ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[™], sold in select markets globally.

For more information, visit www.impedimed.com.

For personal use only